Replies to post #14567 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Anyone ever heard of a Statistician?



Rag on Doc Williams all you want.

Doc Williams wasn't even @ AP when the Topline data readout was made public.

Nor did he interpret the data on behalf of AP. That was the Statisticians job right?

What we do know is Doc Williams is not a part of a Team of Cobras with a long history of pennyland companies that have gone up in smoke and flamed out.

55

IMO AGN is just now Attempting to UNDO the Damage Dr M Williams did by being too Dumb a Scientist to correctly evaluate the Interim AND FINAL Data. The Scientific failures were only surpassed by the dismal Presentations by the CSO.
Yes, CM and the BOD brought in a different team for the 'International' 2b/3 Trial, Right? Dr.MW was busy elsewhere as you pointed out.

HUH? Are you claiming the CEO Drama Queen took a back seat to any webcast regarding science? If so, provide a link. Thus far CJM has not allowed anyone to stand out in any webcast. The closest thing to it would be the DMT webcast @ Biopub with Dr. Nutt and CJM. Mainly because the DMT angle is way over the CEO’s head. At least until he finishes reading “The Spirit Molecule” book from cover to cover.

ROTFLMAO

As to Team Cobra having “brought in a different team…” I have no idea what you’re talking about. It’s the same team minus Doc Williams now. How was Doc Williams MIA during his tenure @ AP? Are you confusing him with Rajpaul, Michael, or David - the "Ghost Ship" Board of Directors?

CJM 12/15/2020

“While we are very pleased that the interim data has provided us with some positive trending information, we still need to evaluate the full definitive results and statistics to be presented with the final data set,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “We will be especially interested to see the numbers on the overall time spent on ventilation and rate to ventilation to be reported in the final data set.”

Yeah...Doc Williams had his hand up the CEOs bum to say ^that in black and white.

CJM 12/17/2020

“We were very pleased to see positive trending data with a ventilation related endpoint that is favoured by the FDA for COVID-19 trials. Further, Algernon has only provided interim data on three endpoints from day 15 of its 30-day Phase 2b/3 Ifenprodil COVID-19 study, with the majority of the data still to be reported.”

Yeah...Doc Williams had his hand up the CEOs bum to say ^that in black and white.

CJM 12/30/2020

“While we have made significant progress this past year aggressively advancing our re-purposed drug compound Ifenprodil, by initiating two Phase 2 clinical trials and accomplishing additional related goals and milestones, we are planning for an even more active 2021,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.

Thus far do things feel more or less active this year than last year? We are almost at the halfway mark. IMO, it feels like new BS on top of old BS. Which equals the same ole bullsh!t.

CJM 02/10/2021

“If we determine that X-rays were taken on release of a meaningful number of our treated patients, and Ifenprodil is showing a reduction in the amount of scarring post infection, this would be an extremely important discovery for us,” said Christopher J. Moreau, CEO of Algernon. “If this is confirmed in the planned Phase 3 portion of the study, it would mean that Ifenprodil could be used to treat patients who have survived COVID-19 but are suffering from lung damage.”

Have you since heard anything new about the X-rays?

Attention: Fire in COVID-19 Hospital in Second World Country of Romania delays the Topline Data readout.

75% of ALL COVID-19 patient records were stored in the Romania hospital!

OOPS

Data Delay Delay Delay Delay

I wonder if Doc Williams had a heavy hand in that “SUPER cost effective” decision to go All In in Romania?

Just like All In in Australia & New Zealand!

Oh Look!

Three and One Half Months (3.5) after receiving COVID-19 Interim Data we finally get COVID-19 Topline Data:

CJM 03/31/2021

“The Company has done a tremendous amount of work in a very short period of time to get to this stage to see if Ifenprodil could help in the world’s fight against COVID-19”, said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “We look forward to completing our data review and receiving feedback from the U.S. FDA.”

Doc Williams had left the building by ^that time.

Meanwhile...the data drips are for sale to any newbies giving AP a new look.

However, longs know all that's new @ AP is all that's old @ AP.

S.O.S. different day for more dilution in the offering.

Here's AP's money making CEO strutting his stuff like a pennyland peacock when no one's around:

www.youtube.com/watch?v=yMK1YMXu35A

Furthermore, who is still not aware of the fact the clinical trial data is independently analysed? One attempts to make it sound like the data results all fall/fell on the CSO shoulders. It does not, did not, and will not. CJM is the dude out front (CEO) playing with the data one way or another in the webcasts. Go back and read GVX808's last post. 808 gets the big picture just like many others that are in tune with the facts.

Last point about Doc Williams. Simply look at his pedigree besides his college degrees (Ph.D, MBA). Does anybody know if the CEO Moreau even has a high school diploma? However, I digress. Doc Williams last biotech gig prior to joining AP in a takeover by Nash Pharmaceuticals (said to be a subsidiary of Breathtec Biomedical) was DiaMedica Therapeutics. They trade on NASDAQ. Their 6 month stock chart shows a share price of approximately $4 to $10 USD. That equates to a market cap of $75M USD to $187M USD. Their current market cap is $122M USD. DiaMedica Therapeutics is effectively a one compound (DM199) one trick pony biotech company. Doc Williams is a co-inventor of DM199. It should also come as no surprise that AP went the route of Ischemic Stroke with it's DMT program. Especially when one considers the "CEO" left it in the hands of Doc Williams to brainstorm a clinical trial pathway for DMT. @ Diamedica, DM199 is being evaluated in a clinical trial for Acute Ischemic Stroke.

Who Knew?!

While we're on the topic of compounds let's see whose name is on ALL relevant patents @ AP to date:

patentscope.wipo.int/search/en/result.jsf?_vid=P11-KOPQQ6-17036

patentscope.wipo.int/search/en/result.jsf?_vid=P11-KOPQQ6-17036

I count 16 patents for Doc Williams and 0 (Zero) patents for Team Cobra @ AP.

We have a CEO who talked about a $500M CAD market cap @ AP at this “Inflection Point” of the process (Phase II Data Readout). He also said "Everybody want's in at Phase II" - CJM, CEO @ AP

^That being said - should we expect a share price increase from the teen cents (10 to 19 cent usd) to $3 USD = $3.63 CAD before another PP for Pals and/or the start of Phase III?

Thus far all we can expect to get out of tacky Mackie and Research Capi is sh!t getting ever more wacky.

04/01/2021 Mackie Research: 25 Cent CAD “HOLD”.

www.cantechletter.com/2021/04/take-a-pass-on-algernon-pharmaceuticals-says-mackie/

05/11/2021 Research Capital: 25 Cent CAD “SPECULATIVE BUY”.

www.cantechletter.com/2021/05/algernon-upgraded-at-research-capital/

Andre Uddin is the same analyst at Mackie Research and Research Capital dropping bombs on the rooftop of AP.

Nick Wadell (Author) is the autopilot for the AP BOMBS AWAY messaging across multiple platforms:

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.



My guess is Andre Uddin & Nick Wadell (Tag Team) will keep pounding the same message over and over again at least until we get feedback from the EOP2 meeting.

Meanwhile...not one word from the AP bunker about the pundits pounding out loud.

I wonder who would stand to gain the most from such a consistent pounding of the chest?

Perhaps the King Kong of Penny Flippers?



Who Knows...right?

AYO!

Make the call - to get the call - for when we all - can expect an “analyst” to call for $3 USD @ AP.

M$

PostScript from the other side of Dante's Inferno:

He made it out Alive with his reputation intact and 16 AP Patents Pending.

Outro